Sopharma Trading AD (XBUL:SFT) Total Equity: €123 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:SFT Sopharma Trading AD XBUL:SFT
82 GF Score
Price €2.86
GF Value €7.67
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD Total Equity?

Sopharma Trading AD XBUL:SFT 82 Total Equity is €123 Mil as of Mar. 2026. GuruFocus rates XBUL:SFT with a GF Score™ of 82/100 and a GF Value™ of €7.67 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Sopharma Trading AD's total equity for the quarter that ended in Mar. 2026 was €123 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sopharma Trading AD Total Equity Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD Total Equity Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.26 47.90 62.63 83.79 112.47

Sopharma Trading AD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.12 104.08 110.22 112.47 122.86
XBUL:SFT
82GF Score
Sopharma Trading AD XBUL:SFT
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma Trading AD Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sopharma Trading AD's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=477.684-365.214
=112

Sopharma Trading AD's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=484.036-361.179
=123

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €123 Mil mean?
Sopharma Trading AD (XBUL:SFT) has a Total Equity of €123 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Sopharma Trading AD and its competitors.
Is Sopharma Trading AD's Total Equity too high?
Sopharma Trading AD's current Total Equity is €123 Mil. Overall, Sopharma Trading AD has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Total Equity compare to MCK and CAH?
Sopharma Trading AD's Total Equity of €123 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Distribution company?
A good Total Equity depends on the Medical Distribution industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sopharma Trading AD and its competitors. Sopharma Trading AD's current Total Equity is €123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.67, compared to a current price of €2.86 — trading 62.7% below its estimated fair value. The current Total Equity is €123 Mil. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current Total Equity is €123 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €2.86 is trading 62.7% below its estimated GF Value™ of €7.67. GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.

Key valuation signals for XBUL:SFT:

  • Total Equity: €123 Mil
  • GF Value™: €7.67 vs. price of €2.86 (62.7% below fair value)
  • GF Score™: 82/100 with 2 warning signs

No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma Trading AD Business Description

Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score

Get the complete analysis for XBUL:SFT

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.86
Price
€7.67
GF Value